Filing Flows

Filing Flows › Usana Health Sciences (USNA) › Q1 2025

Usana Health Sciences (USNA) Q1 2025 earnings results (first quarter 2025)

10-Q filed May 6, 2025

Usana Health Sciences (USNA) reported revenue of $250M for the first quarter 2025 (Q1 2025), +10% from a year earlier and +17% from the quarter before. Operating margin was 6.3%, net earnings $9.3M (3.7% of revenue).

Revenue$250M
Year over year+10%
Quarter over quarter+17%
Operating margin6.3%
Net earnings$9.3M

Usana Health Sciences, Q1 2025: revenue $250M (+10% year over year), operating margin 6.3%, net earnings $9.3M, operating cash flow $15.5M. The chart follows the revenue to costs, profit and cash.

Q1 2025AmountQ/QY/Y
Revenue$250M+17%+10%
Gross profit$197M+13%+7%
Operating profit$15.7M+91%-36%
Net earnings$9.3M+107%-44%
Operating cash flow$15.5M+168%-12%
Free cash flow$12.7M+218%-12%

What changed

Revenue was $249.5M in Q1 2025, up 10% year over year and up 17% from the previous quarter.

Gross margin was 79.0%, down 2.1 points from a year earlier. Operating profit was $15.7M, a 6.3% margin (down 4.6 points year over year). Operating profit fell $9.0M even though revenue rose $21.7M versus a year earlier, so costs grew faster than sales. Operating expenses grew 13% against revenue growth of 10%. The fastest-growing cost line was SG&A (+42%). Net earnings were $9.4M, down 43% year over year. The effective tax rate was 44.5%.

Operating cash flow was $15.5M (down 12% year over year), 167% of net earnings. Non-cash charges added back $8.3M of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items used $5.0M. Capital expenditures of $2.8M left free cash flow of $12.7M.

Questions

What was Usana Health Sciences' revenue in the first quarter 2025?

Usana Health Sciences (USNA) reported revenue of $250M for the first quarter 2025 (Q1 2025), +10% from a year earlier and +17% from the quarter before.

Was Usana Health Sciences profitable in the first quarter 2025?

Operating profit was $15.7M (6.3% of revenue) and net earnings $9.3M.

Open the interactive Sankey →

Source: Usana Health Sciences 10-Q on SEC EDGAR.